Adverum Biotechnologies, Inc Appoints Jim Wang as Senior Vice President, Head of Regulatory Affairs
August 23, 2021 at 02:00 pm
Adverum Biotechnologies, Inc. announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverum’s president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the company’s product pipeline. He brings more than 17 years of global regulatory experience, including a decade in gene therapy that includes the submission and approval for LUXTURNA®, the first gene therapy targeting a genetic disease that received regulatory approval in both the U.S. and EU.